Gliclazide: The effects on lipids in type II diabetes

Delargy, M.; McGovern, Mark E.; Johnson, Alan; Tomkin, G. H.

doi:10.1007/bf02937225

Cited by 3 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…with obesity status. Figure 3.12 shows that in patients with high and very high TG or (TG greater than 2.3), Gliclazide is mostly ineffective, which is also discussed in Delargy et al (1985). The modular EMRS outperforms and improves both individual modules' performance by applying a switching technique.…”

Section: Therapy Analysismentioning

confidence: 83%

Management of Type 2 Diabetes -- Applications of Machine Learning and Electronic Medical Records-based Analytics

Dekamin

2024

Preprint

View full text Add to dashboard Cite

Diabetes mellitus is one of the most severe chronic diseases worldwide and will become the seventh leading cause of death by 2030. To increase the quality of care for Type 2 Diabetes with low side effects methods, three main interrelated levels, including predicting, controlling, and preventing, are investigated in decision support systems. Classification is one of the methods used to provide insight into predicting the future onset of Type 2 diabetes (T2D) in those at high risk of progression from pre-diabetes to T2D. However, imbalanced class distribution is one of the limitations in electronic medical records that leads to patients' misclassification and poor predictive performance. A novel balancing method for improving T2D prediction performance in imbalanced electronic medical records by utilizing a fixed partitioning distribution scheme capable of keeping valuable information besides balancing the data is developed. Drug response prediction and medicine recommendations by utilizing various machine learning techniques have been investigated in recent years. Rapid clinical decisions in the early stages of the disease and accurate medicine recommendations based on past experiences can lower the patients' life-threatening. However, how medicine recommenders and treatment response prediction can be combined and how medicine recommenders can recommend only effective medicines have not yet been investigated. A modular effective anti-diabetic drugs recommender using the glycated hemoglobin indicator before and after using antidiabetics is developed to estimate the medication effectiveness. The proposed model recommends the most appropriate antidiabetic for each individual based on the patient’s characteristics using a hybrid switching method containing the prediction-based and clustering-based modules. The explainability of the proposed model helps extract meaningful patterns from the data that can be applied in controlling T2D. At the causal discovery level, We conduct the first population-based cohort study using a subset of data from the Canadian Primary Care Sentinel Surveillance Network from 2000 to 2015. Cox proportional hazards (PH) regressions are conducted to estimate our primary outcome, time to T2D among prediabetics. In addition, causal mediation analysis decomposed the total effect estimate of cardiovascular disease risk on developing T2D into natural direct and indirect effects through Statin therapy.

show abstract

Section: Therapy Analysismentioning

confidence: 83%

Management of Type 2 Diabetes -- Applications of Machine Learning and Electronic Medical Records-based Analytics

Dekamin

2024

Preprint

View full text Add to dashboard Cite

show abstract

Insulin: Either Alone or Combined with Oral Hypoglycemic Agents

Firth

1988

Primary Care: Clinics in Office Practice

View full text Add to dashboard Cite

Gliclazide

Palmer¹,

Brogden²

1993

Drugs

167

View full text Add to dashboard Cite

Gliclazide is a second generation sulphonylurea oral hypoglycaemic agent used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It improves defective insulin secretion and may reverse insulin resistance observed in patients with NIDDM. These actions are reflected in a reduction in blood glucose levels which is maintained during both short and long term administration, and is comparable with that achieved by other sulphonylurea agents. Gradually accumulating evidence suggests that gliclazide may be useful in patients with diabetic retinopathy, due to its haemobiological actions, and that addition of gliclazide to insulin therapy enables insulin dosage to be reduced. Thus, gliclazide is an effective agent for the treatment of the metabolic defects associated with NIDDM and may have the added advantage of potentially slowing the progression of diabetic retinopathy. These actions, together with its good general tolerability and low incidence of hypoglycaemia have allowed gliclazide to be well placed within the array of oral hypoglycaemic agents available for the control of NIDDM.

show abstract

Gliclazide: The effects on lipids in type II diabetes

Cited by 3 publications

References 13 publications

Management of Type 2 Diabetes -- Applications of Machine Learning and Electronic Medical Records-based Analytics

Management of Type 2 Diabetes -- Applications of Machine Learning and Electronic Medical Records-based Analytics

Insulin: Either Alone or Combined with Oral Hypoglycemic Agents

Gliclazide

Contact Info

Product

Resources

About